VXRT inventory forecast 2025 refers back to the predicted efficiency of the inventory of Vaxart, Inc. (VXRT) within the 12 months 2025. Inventory forecasts try to predict the long run worth of a inventory based mostly on varied components equivalent to the corporate’s monetary efficiency, business tendencies, and general financial circumstances.
VXRT is a clinical-stage biotechnology firm targeted on growing oral vaccines for infectious ailments. The corporate’s lead product candidate is VXA-CoV2-1, an oral vaccine for COVID-19. Vaxart has additionally developed oral vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV).
